men underwent open retropubic RP. BCRs were managed using salvage radiation therapy (SRT), androgen deprivation therapy (ADT) or active surveillance (AS). BCR-free survival was assessed using Kaplan-Meier analysis. Factors predicting earlier or later BCR and BCR after SRT were assessed using logistic regression andCox proportional hazard models, respectively.
Introduction
Approximately 100 000 radical prostatectomy (RP) procedures are performed annually in the USA with the intent to cure clinically localized prostate cancer [1] . Oncological control after RP is assessed by monitoring serum PSA levels [2] . By consensus, a PSA level >0.2 ng/mL is considered the threshold for biochemical recurrence (BCR) after RP [3] . BCR often predates radiographic and clinical evidence of disease recurrence by many years [4] [5] [6] .
Occurrence of BCR may result from residual benign or malignant prostate tissue. The sites for malignant PSA production include the prostatic resection bed vs nodal or systemic metastasis. The site of the disease recurrence along with the PSA doubling time (PSADT) and life expectancy dictates appropriate management. There is a paucity of literature characterizing earlier vs later BCR after RP. The objective of the present study was to examine the preoperative characteristics, pathological assessment of the surgical specimen, PSADT and response to treatment in order to provide insights regarding the aetiology and optimum management of BCR.
Materials and Methods
Between October 2000 and December 2009, 1647 consecutive men who underwent RP, with an open retropubic approach, by a single surgeon (H.L.) were invited to participate in a prospective longitudinal outcomes study approved by the New York University School of Medicine Institutional Review Board. The men were accurately informed and consent was obtained from all but 31 men, who were therefore not enrolled in the present outcomes study. In addition, three men who received androgen deprivation therapy (ADT) preoperatively and 16 men with positive lymph nodes at the time of RP were excluded from the study.
Information relating to demographics, baseline disease characteristics, pathological examination of the surgical specimen including surgical margin status, functional status, all post-treatment interventions and PSA levels were entered in real time into a computer database, which was maintained by dedicated data managers. Relevant information was extracted from the database. PSA levels were obtained at baseline and at 3, 6, 12, 18, 24, 30 and 36 months, and annually thereafter. Additional PSA levels were obtained as clinically indicated. An effort was made by the data manager annually to contact all study participants via US mail or telephone in order to maximize follow-up.
The definition of BCR after RP was at least two consecutive PSA levels of ≥0.2 ng/mL. No men were managed with adjuvant radiation therapy or ADT. We defined earlier and later BCR as BCR occurring before and after 5 years of surgical intervention, respectively.
The treatment options at the time of BCR included active surveillance (AS), salvage radiation therapy (SRT) and ADT. The treatment decision was influenced by PSADT and life expectancy.
Statistical Methods
Rates of BCR-free survival were assessed using KaplanMeier analysis. A logistic regression model was used to assess factors predicting earlier vs later BCR and a Cox proportional hazards model (stepwise method) was used to assess the predictors of BCR after SRT. Variables having a significant univariate test were selected for multivariate analysis to assess predicting factors. Variables presenting sparseness in the data (clinical stage and PSA nadir ≤0.05 ng/mL) were removed from the logistic regression model. Continuous variables were compared using the Mann-Whitney U-test or Kruskal-Wallis H-test. Categorical variables were compared using the chi-squared test. All tests were two-sided using significance levels a = 0.05. All statistical analyses were performed in IBM SPSS statistics version 23 (IBM Corp., Armonk, NY, USA).
Results
Of the 1647 consecutive men who underwent RP between October 2000 and December 2009, 1597 (97%) who signed informed consent to participate in a longitudinal outcomes study were included. The median (interquartile range) followup for the study cohort was 96 (72) months. In all, 182 and 70 men developed BCR <5 years after RP (earlier BCR) and > 5 years after RP (later BCR), respectively. (Table 2) .
Overall, 122 (80.8%), 22 (14.6%) and seven men (4.6%) in the earlier BCR group and 36 (59%), five (8.2%) and 20 men (32.8%) in the later BCR group underwent SRT, ADT and AS, respectively (Fig. 2) . The management strategies for men with earlier vs later BCR were significantly different (P < 0.001). Overall, a significantly greater proportion of men in the earlier BCR group underwent SRT and a significantly (Table 3) . Median age at RP, time to BCR, biopsy Gleason score, pathological Gleason score, PSA nadir ≤0.05 ng/mL, and PSADT were significantly different between the three treatment groups. Preoperative PSA level, pathological stage and rate of positive margins were not significantly different amongst the groups. Pairwise comparison showed the following significant differences between AS and ADT: men undergoing AS were younger, exhibited a longer time to BCR, had lower biopsy and pathological Gleason scores, had longer PSADT and were more likely to achieve a PSA nadir <0.05 ng/mL. Pairwise comparisons showed the following significant differences between AS vs SRT: men undergoing AS had a longer time to BCR and a longer PSADT. Pairwise comparison showed the following significant differences between SRT vs ADT: men undergoing SRT were younger, had a longer time to BCR, had a longer PSADT, had a higher likelihood of achieving a PSA nadir ≤0.05 ng/mL, and had lower biopsy and pathological Gleason scores.
In all, 112 men in the earlier BCR group and 35 men in the later BCR group underwent SRT and were evaluable 3 years after SRT. The median age at RP, Gleason score on biopsy, pathological stage, rate of positive margins and PSADT were not significantly different between the earlier and later BCR groups who underwent SRT ( Table 4) . As expected, men in the earlier BCR group undergoing SRT had a significantly shorter time to BCR and higher median preoperative PSA levels, pathological Gleason scores and rates of undetectable nadir PSA.
The response to SRT was ascertained as: no change or increase in PSA level; a PSA nadir <0.2 ng/mL and a subsequent rise in PSA level; and a PSA nadir <0.2 ng/mL without a subsequent rise in PSA. Only the 68 men with durable PSA response were considered responders to SRT (Table 4) . On univariate analyses, higher clinical stage, pathological stage and Gleason score after RP, and PSA nadir >0.05 ng/mL were significantly associated with failure of SRT (Table 5 ). Earlier vs later BCR was not a predictor of durable response to SRT. On multivariate analyses using a stepwise Cox proportional hazard model including significant univariates, only clinical stage T3-4 (hazard ratio 9.5, 95% CI: 2.156-41.408; P = 0.003) and pathological stage T3-4 (hazard ratio 1.9, 95% CI: 1.2-3.201; P = 0.007) were independent predictors of failure of SRT.
Discussion
Despite the profound stage migration that has been attributed to PSA screening [7] , a significant proportion of men with screen-detected prostate cancers will develop BCR after RP. Mullins et al. [8] recently reported 30-year oncological outcomes of 4478 open RPs performed by a single surgeon (Patrick C. Walsh) between 1982 and 2011 at the Johns Hopkins Hospital. The reported 10-, 15-, 20-and 25-year rates of BCR were 18, 22, 26 and 32%, respectively. The rates of BCR were significantly higher for men undergoing RP between 1982 and 1992 (earlier PSA era) compared with the period 1992 to 2012 (later PSA era), which was explained by a trend to detect and treat lower-risk disease in the later PSA era.
Other investigators have assessed oncological control after RPs performed exclusively within the later PSA era. Brath et al. [9] reported the largest such series; 7690 men undergoing RP were enrolled in a prospective study beginning in 1994. The 10-year BCR rate was 37.5%.
Since the 'later' era of PSA screening, AS has emerged as a standard of care for selected cases of low-risk prostate cancer; therefore, men undergoing RP since 2000 represent a cohort more similar to contemporary surgical candidates. Diaz et al. [10] recently reported a single-institution series of 483 robotassisted laparoscopic RPs performed between 2001 and 2003. A total of 27% of men developed BCR within 10 years, of whom 30% developed BCR between 5 and 10 years after RP.
In the present study, the 10-year progression-free survival rate after open RP was 82%. Our BCR rates are lower than those of Diaz et al. [10] and Brath et al. [9] and similar to those of Mullins et al. [8] While this discrepancy may be attributed to patient selection and intensity of follow-up, the percentages of men with Gleason 6 disease in the studies by Diaz et al. and Mullins et al. and the present study were 61.3, 78.2 and 64.6%, respectively. The lower rates of Gleason 6 disease in the two more contemporary series may reflect patient selection and the impact of AS for low-risk disease.
To our knowledge, the unique aspect of the present study is the comparison of baseline disease risk, pathological findings and PSA nadir between men with earlier BCR vs later BCR and the comparison of management and outcomes for men with earlier vs later BCR.
Men who experienced later BCR had significantly lower biopsy Gleason scores, pathological stage, pathological Gleason score, positive margin rates and preoperative PSA level, a higher likelihood of achieving an undetectable PSA nadir and significantly longer PSADT than those with earlier BCR. On multivariate analysis, men with later BCR had lower pathological Gleason scores, lower rates of positive surgical margins, and higher PSADT, suggesting that, overall, earlier BCR represents more aggressive disease.
Men developing BCR after RP were managed with SRT, ADT or AS. SRT was generally recommended when the BCR was felt to be biologically significant and was locally confined to the prostate bed. We have previously shown that the overwhelming majority of men with a PSADT of <3 months at the time of developing BCR have demonstrable metastatic disease [11] ; therefore, cases with very short PSADT were generally offered ADT. We have also shown that upwards of 50% of men will have some benign elements at the apical and bladder neck soft tissue margins [12] . Within the first few years after RP these microscopic elements do not appear to produce enough PSA to be detectable [13] ; however, over 10 years, we hypothesize these residual benign elements may ultimately raise the PSA level above the threshold for BCR, however the PSADT should be prolonged. Many men with prolonged PSADT were, therefore, managed with AS. A comparison of disease risk factors showed that men treated with ADT, SRT and AS had the most aggressive, intermediate-and low-risk disease, respectively.
Specifically, of the men developing BCR, 158, 27 and 27 were managed with SRT, ADT and AS, respectively. Men with PSADT <3 months were all managed with ADT. Men with PSADT between 3 and 6 months were managed with ADT or SRT, all men with PSADT between 6 and 24 months underwent SRT and men with PSADT between 2 and 3 years underwent SRT or AS.
In all, 14.6, 80.8 and 4.6% of men with earlier BCR and 8.2, 59 and 32.8% of men with later BCR underwent ADT, SRT and AS, respectively. Overall, SRT was offered to 74.5% of men developing BCR. Biopsy Gleason score, pathological stage, positive margin rate and PSADT were not significantly different between the men with earlier vs later BCR who underwent SRT. Univariate and multivariate analyses showed that, in the present cohort, the time to development of BCR was not a factor predicting durable response to SRT. In conclusion, of the 18% of men who developed BCR after RP within 10 years of surgical intervention, the ratio of earlier vs later BCR was 2:1. Men with earlier BCR had more aggressive disease. The present study provides compelling evidence that men with earlier vs later BCR after RP have different aetiologies for rising PSA levels. Based on PSADT, all cases of earlier BCR were presumed to be clinically significant and the overwhelming majority were treated with SRT or ADT. About one third of cases of later BCR were associated with a very prolonged PSADT which was attributed to benign prostatic elements or very-low-risk disease and these cases were managed with AS. The disease characteristics of men with earlier vs later BCR who were offered SRT were similar; therefore, it is not surprising that the response to SRT in the present cohort was independent of time to BCR. Long-term follow-up is mandatory after RP, but the possibility of benign BCR must be considered in men receiving such follow-up.
